Quick Links: Skip to main page content Skip to Search Skip to Topics Menu Skip to Section Content Menu Skip to Common Links
  • Decrease font size
  • Return font size to normal
  • Increase font size
U.S. Department of Health and Human Services

Safety

  • Print
  • Share
  • E-mail
-

Exelon (rivastigmine tartrate)

Changes to Prescribing Information for Exelon. The changes provide guidelines for reinitiating therapy in patients who have interrupted treatment with Exelon, to reduce the risk of severe vomiting.

[January 31, 2001 - Letter - Novartis Pharmaceuticals]

-
-